Abstract
References
Goemaere S, Ackerman C, Goethals K, et al. Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. J Rheumatol 1990; 17(12): 1620-2.
Wasserman A. Rheumatoid arthritis: common questions about diagnosis and management. Am Fam Physician 2018; 97(7): 455-62.
Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59(12): 1690-7. Available from: https://doi.org/10.1002/art.24092
Low AS, Symmons DP, Lunt M, et al. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis 2017; 76(4): 654-60. Available from: https://doi.org/10.1136/annrheumdis-2016-209784
Monti S, Montecucco C, Bugatti S, Caporali R. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open 2015; 1(Suppl 1): e000057. Available from: https://doi.org/10.1136/rmdopen-2015-000057
Rheumatoid arthritis in adults: management NICE guideline [NG100]. https://www.nice.org.uk/guidance/ ng100/chapter/Recommendations - non-pharmacological management (accessed 08/03/2020).
Mitrovic SP, Taylor P, Fautrel B. Module 4 treatment of rheumatoid arthritis. Eular on- line course on Rheumatic diseases.
European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf.
Smolen JS, Goncalves J, Quinn M, Benedetti F, Lee JY. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open 2019; 5(1): e000900. Available from: https://doi.org/10.1136/rmdopen-2019-000900
Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of non-biologic and biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59(6):762-84.